Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
Steven A. Rosenberg(National Cancer Institute), Donald E. White(National Institutes of Health), Suzanne L. Topalian(Bloomberg (United States)), Sharon Mavroukakis(Stanford Medicine), Dennis Panicali(Fox Chase Cancer Center), Claudia A. Seipp, Linda Gritz, Nicholas P. Restifo(Lyell Immunopharma (United States)), Richard M. Sherry(Unknown), Linda Rogers-Freezer, James C. Yang(National Taiwan University Hospital), John R. Wunderlich, Kathleen E. Morton, Douglas J. Schwartzentruber(Goshen Health), Patrick Hwu(Moffitt Cancer Center)
PubMed
August 1, 2003
Cited by 90
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
A human memory T cell subset with stem cell–like properties
|Nature Medicine|2011|2k